SY-5609 is a small molecule commercialized by Syros Pharmaceuticals, with a leading Phase I program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to Globaldata, it is involved in 3 clinical trials, of which 1 is ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of SY-5609’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for SY-5609 is expected to reach an annual total of $116 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
SY-5609 is under development for the treatment of triple-negative breast cancer, small cell lung cancer, colorectal cancer, HER2 negative metastatic breast cancer, ovarian cancer, metastatic pancreatic cancer(pancreatic ductal adenocarcinoma), mantle cell lymphoma and other solid tumors. It is administered orally. The drug candidate acts by targeting Cyclin Dependent Kinase 7 (CDK7).
Syros Pharmaceuticals Overview
Syros Pharmaceuticals (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials including Tamibarotene, an oral potent and selective RARa agonist, SY-2101, a arsenic trioxide (ATO) and SY-5609, a highly selective and potent oral inhibitor. Syors products are used to treat the patients with acute myeloid leukemia and myelodysplastic syndrome (MDS); acute promyelocytic leukemia, pancreatic cancer and BRAF-mutant colorectal cancer. It also provides gene regulation, new medicines development, proprietary drug development platform, and integrated gene control assay technologies. The company’s gene control platform identifies novel gene control targets linked to genomically defined patient populations and drugging gene control targets. It partners with other biopharmaceutical companies to extend the potential of our gene control platform across multiple therapeutic areas and diseases. Syros is headquartered in Cambridge, Massachusetts, the US
The company reported revenues of (US Dollars) US$14.9 million for the fiscal year ended December 2022 (FY2022), a decrease of 36.6% over FY2021. The operating loss of the company was US$135.9 million in FY2022, compared to an operating loss of US$99.4 million in FY2021. The net loss of the company was US$94.7 million in FY2022, compared to a net loss of US$86.6 million in FY2021.
For a complete picture of SY-5609’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.